Human Monoclonal Antibodies: On the Menu of Targeted Therapeutics Against COVID-19.
Virol Sin
; 35(6): 713-724, 2020 Dec.
Article
in English
| MEDLINE | ID: covidwho-1217485
ABSTRACT
Coronavirus disease 2019 (COVID-19), reminiscent of the severe acute respiratory syndrome (SARS) outbreak in 2003, has been a tragic disaster to people all over the world. As there is no specific drug for COVID-19, neutralizing antibodies are attracting more and more attention as one of the most effective means to combat the pandemic. Here, we introduced the etiological and serological characteristics of COVID-19, discussed the current stage of development of human monoclonal antibodies against SARS-CoV-2 and summarized the antigenic epitopes in the S glycoprotein, which may deepen the understanding of the profile of immune recognition and response against SARS-CoV-2 and provide insight for the design of effective vaccines and antibody-based therapies.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antibodies, Neutralizing
/
SARS-CoV-2
/
COVID-19
/
COVID-19 Drug Treatment
/
Antibodies, Monoclonal
Type of study:
Etiology study
Topics:
Vaccines
Limits:
Animals
/
Humans
Language:
English
Journal:
Virol Sin
Journal subject:
Virology
Year:
2020
Document Type:
Article
Affiliation country:
S12250-020-00327-x
Similar
MEDLINE
...
LILACS
LIS